Forte Biosciences, Inc. Net Income Loss

• Forte Biosciences, Inc. showed a decrease of -95.5% in Net Income Loss from 2024 to 2025.
• This data is from Forte Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2016: -$8.01 million | Q2 2016: -$8.04 million | Q3 2016: -$9.00 million | Q4 2016: -$8.43 million | Q1 2017: -$9.07 million | Q2 2017: -$9.07 million | Q3 2017: -$9.95 million | Q4 2017: -$10.84 million | Q1 2018: -$12.88 million | Q2 2018: -$16.09 million | Q3 2018: -$383.0 thousand | Q4 2018: -$19.60 million | Q1 2019: -$1.19 million | Q2 2019: -$630.0 thousand | Q3 2019: -$690.0 thousand | Q4 2019: -$10.58 million | Q1 2020: -$2.05 million | Q2 2020: -$34.76 million | Q3 2020: -$5.10 million | Q1 2021: -$4.80 million | Q2 2021: -$5.81 million | Q3 2021: -$7.75 million | Q1 2022: -$2.57 million | Q2 2022: -$3.04 million | Q3 2022: -$3.40 million | Q1 2023: -$6.75 million | Q2 2023: -$8.90 million | Q3 2023: -$9.96 million | Q1 2024: -$7.42 million | Q2 2024: -$12.51 million | Q3 2024: -$8.39 million | Q1 2025: -$15.66 million | Q2 2025: -$11.25 million | Q3 2025: -$17.68 million.
• Over the full 11 years of available data (2015 to 2025), Forte Biosciences, Inc.'s Net Income Loss has declined by 200.9%.
• Historical annual values: Fiscal year 2025: -$69.38 million | Fiscal year 2024: -$35.48 million | Fiscal year 2023: -$31.48 million | Fiscal year 2022: -$13.88 million | Fiscal year 2021: -$21.71 million | Fiscal year 2020: -$46.49 million | Fiscal year 2019: -$4.07 million | Fiscal year 2018: -$48.96 million | Fiscal year 2017: -$38.93 million | Fiscal year 2016: -$33.48 million | Fiscal year 2015: -$23.06 million.
• Data sourced from SEC EDGAR public filings as of August 4, 2026.

Last verified: August 4, 2026